The Beatrice Hunter Cancer Research Institute logo
  • Dr. Zhaolin Xu, MD, FRCPC, FCAP


Professor, Department of Pathology, Faculty of Medicine, Dalhousie University 

Pulmonary Pathologist and Cytopathologist, QE II Health Sciences Centre, NSHA

Chair, Pathology Working Group and Network Member, Pan-Canadian Lung Cancer Screening Network, Canadian Partnership Against Cancer (CPAC)

Chair, Pathology Working Group and Steering Committee Member, Lung Cancer Screening Network, Cancer Care Nova Scotia (CCNS) 

Committee Member, Correlative Sciences and Tumor Biology Committee, and Lung Tumor Sub-committee, Candian Clinical Trial Group (CCTG) 

Expert Panel Member, Lung National Cancer Pathology and Staging Multidisciplinary Expert Panel, Canadian Partnership Against Cancer (CPAC)

Board of Directors and Medical Advisory Committee Member, Lung Cancer Canada (LCC) 

Cancer Protocol Review Penal, Lung and Mediastinal Tumors, and Gynecologic Tumors, College of American Pathologists


Dalhousie University, Faculty of Medicine Queen Elizabeth II Health Sciences Centre, Capital Health

Research Interests:

Lung cancer genotyping and molecular profiling, Lung tumor banking, Metastasis and early detection of lung cancer

Molecular classification of lung cancer is essential in modern oncology

Molecular classification of lung cancer based on gene mutational status has a significant impact on patient’s clinical management that is considered as one of the new directions in modern oncology. Dr. Zhaolin Xu is studying gene mutations in human lung cancer in addition to pathological assessment of the tumor. Lung cancer patients can be divided into various subgroups based on not only tumor morphology but also molecular profiling, and selected to receive personalized targeted therapy accordingly. Dr. Xu and his colleagues have established the QE II Lung Tumor Bank for research since 2005, which is certified by the Canadian Tumor Repository Network (CTRNet). Dr. Xu is the Director of the tumor bank which has become one of the largest human lung tumor banks in the country. Dr. Xu’s research interest also includes lung cancer metastasis and early detection, and immune checkpoints in lung cancer.

Involvement with BHCRI to date:

Dr. Xu is a BHCRI Senior Scientist and has been a BHCRI Seminar Series presenter.





Mackenzie Building, 5788 University Ave., Halifax NS B3H 1V8


Xu Z. Pulmonary Pathology in Pathology Review (2nd ed) ed. Zu-Hua Gao, Brush Educarion Inc. 2017 

Tammemagi MC, Schmidt H, Martel S, McWilliams A, Goffin JR, Johnston MR, Nicholas G, Tremblay A, Bhatia R, Liu G, Soghrati K, Yasufuku K, Hwang DM, Laberge F, Gingras M, Pasian S, Couture C, Mayo JR, Fauerbach PVN, Atkar-Khattra S, Peacock SJ, Cressman S, Ionescu D, English JC, Finley RJ, Yee J, Puksa S, Stewart, Tsai S, Haider E, Boylan C, Cutz JC, Manos D, Xu Z, Goss GD, Seely JM, Amjadi K, Sekhon HS, Burrowes P, MacEachern P, Urbanski S, Sin DD, Tan WC, Leighl NB, Shepherd FA, Evans WK, Tsao MS, Lam S. Participant Selection by Risk Model - the Pan-Canadian Study, The Lancet Oncology 2017 D-17-00805R3 

Cressman S, Peacock SJ, Tammemagi M, Evans WK, Leighl NB, Tremblay GA, Liu G, Manos D, MacEachern P, Bhatia R, Puksa S, Nicholas G, McWilliams A, Yee MJ, English JC, Pataky R, McPherson E, Atkar-Khattra S, Johnston MR, Schmidt H, Shepherd FA, Soghrati K, Amjadi K, Burrowes P, Couture C, Sekhon HS, Yasufuku K, Goss G, Ionescu DN, Hwang DM, Martel S, Sin DD, Tan WC, Urbanski S, Xu Z, Tsao MS, Stephen Lam S The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency Journal of Thoracic Oncology May 9, 2017 DOI: 10.1016/j.jtho.2017.04.021 

Williams A, Greer W, Bethune D, Craddock K, Flowerdew G and Xu Z. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization. Virchows Archiv 2016; 469(5): 533-540 

Rama K. Singh, Jeffrey W. Gallant, Wenda Greer, Zhaolin Xu and Susan E. Douglas An Unbalanced Exon-Expression qPCR-based Assay for Detection of ALK Translocation (Fusion) in Lung Cancer. Pulmonary Research and Respiratory Medicine - Open Journal. Accepted Ref. No. PRRMOJ-16-RS114 

Barbara Melosky, Jason Agulnik; Roula Albadine; Shantanu Banerji; Dafydd G Bebb; Drew Bethune; Normand Blais; Charles Butts; Parneet Cheema; Patrick Cheung; Victor Cohen; Jean Luc Deschenes; Diana N. Ionescu, Rosalyn Juergens; Suzanne Kamel-Reid; Scott Laurie; Geoffrey Liu; Wojciech Morzycki; Ming-Sound Tsao; Zhaolin Xu; Vera Hirsh Canadian Consensus: Inhibition of ALK Positive Tumours in Advanced NSCLC. Current Oncology 2016; 23(3): 196-200 

Ali Sabri, Madiha Batool, Zhaolin Xu, Drew Bethune, Mohamed Abdolell, Daria Manos Predicting EGFR mutation status in lung cancer:Proposal for a scoring model using imaging and demographic characteristics. European Radiology 2016 pp 1-7 10.1007/s00330-016-4252-3 

Xu Z. Significance of Molecular Genotyping for Lung Cancer in Modern Oncology. Pulmonary Research and Respiratory Medicine 2015; 2(3): 120-121 

Singh RK, Bethune DC, Xu Z, and Douglas SE. Role of microRNAs in progression and recurrence of early-stage lung adenocarcinoma. Pulmonary Research and Respiratory Medicine 2015; 2(1): 52-62 

Greer W, Douglas, S, Xu Z, Morzycki W, MacNei M, Stone A, Drew Bethune D. Molecular Diagnostics for Lung Cancer in Atlantic Canada. Canadian Journal of Pathology 2015; 7(1): 20-26

Site by: Spectacle Group